JP2019527537A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527537A5 JP2019527537A5 JP2018564975A JP2018564975A JP2019527537A5 JP 2019527537 A5 JP2019527537 A5 JP 2019527537A5 JP 2018564975 A JP2018564975 A JP 2018564975A JP 2018564975 A JP2018564975 A JP 2018564975A JP 2019527537 A5 JP2019527537 A5 JP 2019527537A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- car
- domain
- polypeptide
- antigen receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 38
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- 229920001184 polypeptide Polymers 0.000 claims 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims 19
- 210000004027 cell Anatomy 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
- 125000006850 spacer group Chemical group 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 230000000139 costimulatory effect Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000011664 signaling Effects 0.000 claims 5
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 4
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 4
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 210000002865 immune cell Anatomy 0.000 claims 3
- 230000003834 intracellular effect Effects 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 108010083359 Antigen Receptors Proteins 0.000 claims 1
- 102000006306 Antigen Receptors Human genes 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010034016 Paronychia Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 101800001707 Spacer peptide Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 102000046935 human TNFRSF17 Human genes 0.000 claims 1
- 210000003519 mature b lymphocyte Anatomy 0.000 claims 1
- 210000001806 memory b lymphocyte Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000002536 stromal cell Anatomy 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022106290A JP7646604B2 (ja) | 2016-06-07 | 2022-06-30 | キメラ抗原受容体と、ｂｃｍａに結合するｃａｒ－ｔ細胞 |
| JP2024154170A JP7805409B2 (ja) | 2016-06-07 | 2024-09-06 | キメラ抗原受容体と、ｂｃｍａに結合するｃａｒ－ｔ細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16173401 | 2016-06-07 | ||
| EP16173401.7 | 2016-06-07 | ||
| PCT/EP2017/063862 WO2017211900A1 (en) | 2016-06-07 | 2017-06-07 | Chimeric antigen receptor and car-t cells that bind bcma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022106290A Division JP7646604B2 (ja) | 2016-06-07 | 2022-06-30 | キメラ抗原受容体と、ｂｃｍａに結合するｃａｒ－ｔ細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019527537A JP2019527537A (ja) | 2019-10-03 |
| JP2019527537A5 true JP2019527537A5 (enExample) | 2020-06-11 |
Family
ID=56112891
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018564975A Pending JP2019527537A (ja) | 2016-06-07 | 2017-06-07 | キメラ抗原受容体と、ｂｃｍａに結合するｃａｒ−ｔ細胞 |
| JP2022106290A Active JP7646604B2 (ja) | 2016-06-07 | 2022-06-30 | キメラ抗原受容体と、ｂｃｍａに結合するｃａｒ－ｔ細胞 |
| JP2024154170A Active JP7805409B2 (ja) | 2016-06-07 | 2024-09-06 | キメラ抗原受容体と、ｂｃｍａに結合するｃａｒ－ｔ細胞 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022106290A Active JP7646604B2 (ja) | 2016-06-07 | 2022-06-30 | キメラ抗原受容体と、ｂｃｍａに結合するｃａｒ－ｔ細胞 |
| JP2024154170A Active JP7805409B2 (ja) | 2016-06-07 | 2024-09-06 | キメラ抗原受容体と、ｂｃｍａに結合するｃａｒ－ｔ細胞 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12048718B2 (enExample) |
| EP (2) | EP3463396B1 (enExample) |
| JP (3) | JP2019527537A (enExample) |
| KR (2) | KR20230042703A (enExample) |
| CN (2) | CN109641012A (enExample) |
| AU (1) | AU2017276706B2 (enExample) |
| CA (1) | CA3026778A1 (enExample) |
| ES (1) | ES3068946T3 (enExample) |
| SG (2) | SG10202012157QA (enExample) |
| WO (1) | WO2017211900A1 (enExample) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12048718B2 (en) * | 2016-06-07 | 2024-07-30 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft | Chimeric antigen receptor and CAR-T cells that bind BCMA |
| US12226479B2 (en) | 2017-05-11 | 2025-02-18 | The General Hospital Corporation | Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| BR112019023608A2 (pt) | 2017-05-12 | 2020-05-26 | Crispr Therapeutics Ag | Materiais e métodos para células manipuladas e seus usos em imuno-oncologia |
| EP3638218A4 (en) | 2017-06-14 | 2021-06-09 | The Broad Institute, Inc. | COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH |
| WO2019014581A1 (en) | 2017-07-14 | 2019-01-17 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE |
| WO2019070755A1 (en) | 2017-10-02 | 2019-04-11 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER |
| WO2019094983A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
| US12171783B2 (en) | 2017-11-13 | 2024-12-24 | The Broad Institute, Inc. | Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas |
| AU2019214183B2 (en) * | 2018-02-01 | 2022-04-07 | Innovent Biologics (Suzhou) Co., Ltd. | Fully human anti-B cell maturation antigen (BCMA) single chain variable fragment, and application thereof |
| CN110662771B (zh) | 2018-02-01 | 2023-07-28 | 南京驯鹿生物技术股份有限公司 | 一种结合bcma的嵌合抗原受体(car)及其应用 |
| ES2968880T3 (es) * | 2018-02-01 | 2024-05-14 | Nanjing Iaso Biotechnology Co Ltd | Receptor de antígeno quimérico (CAR) que se une a BCMA, y usos del mismo |
| KR20200119840A (ko) * | 2018-02-09 | 2020-10-20 | 이매틱스 유에스 인코포레이티드 | T 세포의 제조 방법 |
| CA3090793C (en) * | 2018-02-16 | 2024-10-08 | Kite Pharma, Inc. | MODIFIED MULTIPOTENTED STEM CELLS, AND METHODS OF PREPARATION AND USE |
| CN112074278B (zh) * | 2018-04-03 | 2023-04-25 | 湖南远泰生物技术有限公司 | Bcma-car-t细胞 |
| CN116836297A (zh) * | 2018-04-12 | 2023-10-03 | 上海赛比曼生物科技有限公司 | 靶向bcma的嵌合抗原受体及其制法和应用 |
| US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
| US20200063100A1 (en) | 2018-05-11 | 2020-02-27 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
| GB201807862D0 (en) * | 2018-05-15 | 2018-06-27 | Ucl Business Plc | Chimeric antigen receptor |
| WO2019232542A2 (en) | 2018-06-01 | 2019-12-05 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
| US12036240B2 (en) | 2018-06-14 | 2024-07-16 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| LT4324851T (lt) | 2018-07-19 | 2025-10-10 | Chimeriniai antigeno receptoriai, pasižymintys bcma specifiškumu, ir jų panaudojimas | |
| US20210382068A1 (en) | 2018-10-02 | 2021-12-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
| WO2020081730A2 (en) | 2018-10-16 | 2020-04-23 | Massachusetts Institute Of Technology | Methods and compositions for modulating microenvironment |
| WO2020092455A2 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
| EP3873539A4 (en) * | 2018-10-31 | 2023-01-18 | The Children's Hospital of Philadelphia | LYMPH-BASED T-CELLS FOR DIAGNOSTIC AND THERAPEUTIC USE |
| CN119569895A (zh) | 2018-11-01 | 2025-03-07 | 朱诺治疗学股份有限公司 | G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体 |
| WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
| US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
| PT3749338T (pt) * | 2019-01-16 | 2024-09-20 | Caribou Biosciences Inc | Anticorpo de bcma humanizado e células bcma-car-t |
| CN111454358A (zh) * | 2019-01-18 | 2020-07-28 | 四川科伦博泰生物医药股份有限公司 | 一种嵌合抗原受体及其应用 |
| CA3130489A1 (en) * | 2019-02-18 | 2020-08-27 | Memorial Sloan-Kettering Cancer Center | Combinations of multiple chimeric antigen receptors for immunotherapy |
| WO2020186101A1 (en) | 2019-03-12 | 2020-09-17 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
| EP3942023A1 (en) | 2019-03-18 | 2022-01-26 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
| KR20210143246A (ko) | 2019-03-21 | 2021-11-26 | 리제너론 파아마슈티컬스, 인크. | 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용 |
| AU2020247119A1 (en) * | 2019-03-25 | 2021-09-23 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Enhancement of cytolytic T-cell activity by inhibiting EBAG9 |
| CA3138633A1 (en) | 2019-04-30 | 2020-11-05 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| EP3733707A1 (en) * | 2019-04-30 | 2020-11-04 | Celyad S.A. | Car t-cells targeting bcma and uses thereof |
| CN113784733B (zh) * | 2019-05-07 | 2024-09-06 | 亘喜生物科技（上海）有限公司 | 靶向bcma的工程化免疫细胞及其用途 |
| US20220235340A1 (en) | 2019-05-20 | 2022-07-28 | The Broad Institute, Inc. | Novel crispr-cas systems and uses thereof |
| JP7702884B2 (ja) * | 2019-06-05 | 2025-07-04 | ドイチェス ツェントラム フューア ノイロデジェネラティヴ エアクランクンゲン エー． ファウ．（ディーゼットエヌイー） | 神経学的自己免疫疾患における中枢神経系を標的とする自己抗体に結合するキメラ自己抗体受容体（ｃａａｒ） |
| JP2022541538A (ja) * | 2019-07-19 | 2022-09-26 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | グリピカン２結合ドメインを含有するキメラ抗原受容体 |
| HUE064890T2 (hu) * | 2019-08-02 | 2024-04-28 | Fundacio De Recerca Clinic Barcelona Inst | BCMA elleni CAR T-sejtek mielóma multiplex kezelésére |
| US20220282333A1 (en) | 2019-08-13 | 2022-09-08 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
| US12421557B2 (en) | 2019-08-16 | 2025-09-23 | The Broad Institute, Inc. | Methods for predicting outcomes and treating colorectal cancer using a cell atlas |
| CN114222758A (zh) * | 2019-08-20 | 2022-03-22 | 武汉华大吉诺因生物科技有限公司 | 抗bcma抗体及其在car-t领域中的应用 |
| US20220298501A1 (en) | 2019-08-30 | 2022-09-22 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
| JP2023501871A (ja) * | 2019-09-20 | 2023-01-20 | 上海吉倍生物技術有限公司 | Ｂｃｍａ標的化抗体及びキメラ抗原受容体 |
| US20220378831A1 (en) * | 2019-09-25 | 2022-12-01 | Fate Therapeutics, Inc. | Multi-targeting effector cells and use thereof |
| US12297426B2 (en) | 2019-10-01 | 2025-05-13 | The Broad Institute, Inc. | DNA damage response signature guided rational design of CRISPR-based systems and therapies |
| US12394502B2 (en) | 2019-10-02 | 2025-08-19 | The General Hospital Corporation | Method for predicting HLA-binding peptides using protein structural features |
| US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
| US12195725B2 (en) | 2019-10-03 | 2025-01-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity |
| US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
| CN110669144B (zh) * | 2019-10-12 | 2021-09-17 | 华夏源（上海）细胞基因工程股份有限公司 | 一种靶向b细胞成熟抗原的嵌合抗原受体及其应用 |
| CN110642953B (zh) * | 2019-10-12 | 2021-09-17 | 华夏源（上海）细胞基因工程股份有限公司 | 一种靶向bcma的t细胞受体融合蛋白和应用 |
| US11844800B2 (en) | 2019-10-30 | 2023-12-19 | Massachusetts Institute Of Technology | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia |
| AU2020382219A1 (en) | 2019-11-13 | 2022-05-12 | Crispr Therapeutics Ag | Manufacturing process for making T cells expressing chimeric antigen receptors |
| US12165747B2 (en) | 2020-01-23 | 2024-12-10 | The Broad Institute, Inc. | Molecular spatial mapping of metastatic tumor microenvironment |
| KR102626782B1 (ko) * | 2020-02-14 | 2024-01-19 | 주식회사 셀젠텍 | B세포 성숙화 항원을 표적으로 하는 키메라 항원 수용체 및 이의 용도 |
| EP4161966A1 (en) | 2020-06-05 | 2023-04-12 | Eisai R&D Management Co., Ltd. | Anti-bcma antibody-drug conjugates and methods of use |
| KR102316091B1 (ko) * | 2020-06-17 | 2021-10-25 | 국립암센터 | Bcma를 표적으로 하는 키메라 항원 수용체 및 이의 용도 |
| CN112048481B (zh) * | 2020-09-09 | 2023-02-10 | 广东昭泰体内生物医药科技有限公司 | 一种靶向cd19的嵌合抗原受体nk细胞及其应用 |
| CN112143707A (zh) * | 2020-09-29 | 2020-12-29 | 广东先康达生物科技有限公司 | 一种治疗自身免疫细胞的免疫细胞及其应用 |
| WO2022116086A1 (en) * | 2020-12-03 | 2022-06-09 | Janssen Biotech, Inc. | Bcma-targeted car-t cell therapy for multiple myeloma |
| US20240245722A1 (en) | 2021-05-25 | 2024-07-25 | Vaxcell-Bio | Monobody-based chimeric antigen receptor and immune cell including same |
| CN117730145A (zh) * | 2021-07-16 | 2024-03-19 | 克莱格医学有限公司 | 嵌合抗原受体 |
| WO2023010122A2 (en) * | 2021-07-29 | 2023-02-02 | Sonoma Biotherapeutics, Inc. | Synovial extracellular matrix-specific chimeric antigen receptor for targeting regulatory t cells to treat autoimmune diseases |
| CN115466331B (zh) * | 2021-11-18 | 2023-05-30 | 合源生物科技(天津)有限公司 | 靶向bcma的嵌合抗原受体及其应用 |
| EP4491633A4 (en) | 2022-03-08 | 2026-01-14 | Vaxcell Bio Co Ltd | PD-L1 SPECIFIC CHIMERIC ANTIGENIC RECEPTOR AND IMMUNE CELL CONTAINING IT |
| EP4565262A2 (en) | 2022-08-05 | 2025-06-11 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
| KR20250054790A (ko) * | 2022-08-08 | 2025-04-23 | 티크바 알로셀 피티이. 엘티디. | 키메라 항원 수용체 도메인 |
| EP4598949A1 (en) | 2022-10-07 | 2025-08-13 | The General Hospital Corporation | Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins |
| WO2024124044A1 (en) | 2022-12-07 | 2024-06-13 | The Brigham And Women’S Hospital, Inc. | Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression |
| PE20260290A1 (es) | 2023-03-31 | 2026-02-10 | Abelzeta Inc | Receptores de antigeno quimericos biespecificos dirigidos a cd20 y bcma |
| WO2025031500A1 (zh) * | 2023-08-10 | 2025-02-13 | 深圳市三启生物技术有限公司 | 含有gprc5d抗体的嵌合抗原受体及其应用 |
| WO2025059533A1 (en) | 2023-09-13 | 2025-03-20 | The Broad Institute, Inc. | Crispr enzymes and systems |
| WO2025097055A2 (en) | 2023-11-02 | 2025-05-08 | The Broad Institute, Inc. | Compositions and methods of use of t cells in immunotherapy |
| WO2025117544A1 (en) | 2023-11-29 | 2025-06-05 | The Broad Institute, Inc. | Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof |
| US20250242056A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| WO2025160340A2 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| CN118344480A (zh) * | 2024-03-19 | 2024-07-16 | 浙江康佰裕生物科技有限公司 | 靶向bcma的单域抗体、嵌合抗原受体及其应用 |
| WO2026103881A1 (en) * | 2024-11-15 | 2026-05-21 | Nanjing Legend Biotech Co., Ltd. | Bcma binding moieties and uses thereof |
| WO2026151982A1 (en) | 2025-01-10 | 2026-07-16 | Regeneron Pharmaceuticals, Inc. | Methods of treating food allergy by administering an il-4r antagonist and a bcma targeting agent |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| DK0973928T3 (da) | 1997-03-11 | 2010-08-09 | Univ Minnesota | DNA-baseret transposonsystem til indføring af nukleinsyre i DNA i en celle |
| AU751647B2 (en) | 1998-05-26 | 2002-08-22 | Innogenetics N.V. | Method for expanding primate B cells selectively in immunocompromised mice and producing large numbers of antigen-specific B lymphocytes for the production of primate monoclonal antibodies |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| HK1052372A1 (zh) | 2000-02-24 | 2003-09-11 | Xcyte Therapies, Inc. | 细胞的同步刺激和富集 |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US8236523B2 (en) * | 2004-08-23 | 2012-08-07 | The Johns Hopkins University | Camp reporters and high throughput assays |
| US9228180B2 (en) | 2007-07-04 | 2016-01-05 | Max-Delbruck-Centrum Fur Molekulare Medizin | Polypeptide variants of sleeping beauty transposase |
| RU2011117213A (ru) | 2008-09-30 | 2012-11-10 | Эббот Лэборетриз (Us) | Улучшенные библиотеки антител |
| WO2013075027A2 (en) * | 2011-11-17 | 2013-05-23 | Emergent Product Development Seattle, Llc | Anti-sil6xr complex binding domains and methods of use |
| AU2013246443B2 (en) * | 2012-04-11 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting B-cell maturation antigen |
| CA2876096A1 (en) | 2012-08-02 | 2014-02-06 | Petra Rueger | Method for producing soluble fcr as fc-fusion with inert immunoglobulin fc-region and uses thereof |
| LT2884999T (lt) | 2012-08-20 | 2021-04-12 | Fred Hutchinson Cancer Research Center | Ląstelinės imunoterapijos būdas ir kompozicijos |
| EP2914628A1 (en) | 2012-11-01 | 2015-09-09 | Max-Delbrück-Centrum für Molekulare Medizin | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
| GB201317929D0 (en) * | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| CA2941958A1 (en) * | 2013-12-10 | 2015-06-18 | F. Hoffmann-La Roche Ag | Use of the binding domain of a subunit of a multi-subunit structure for targeted delivery of pharmaceutically active entities to the multi-subunit structure |
| EP3243831A1 (en) | 2014-02-27 | 2017-11-15 | Ucl Business Plc | Variants of the proliferation-inducing ligand (april) |
| EA035266B1 (ru) * | 2014-02-28 | 2020-05-22 | Икнос Сайенсиз Са | Экспрессирующие конструкции и способы для отбора клеток-хозяев, экспрессирующих полипептиды |
| GB201403972D0 (en) * | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| CN106459165B (zh) * | 2014-04-01 | 2021-04-20 | 拜恩科技细胞&基因治疗有限公司 | 密封蛋白-6特异性免疫受体和t细胞表位 |
| SG10201808811QA (en) * | 2014-04-10 | 2018-11-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Method and compositions for cellular immunotherapy |
| EP3131927B8 (en) * | 2014-04-14 | 2020-12-23 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| BR112016024546A2 (pt) * | 2014-04-30 | 2018-01-23 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | anticorpo ou fragmento de anticorpo, anticorpo ou fragmento de anticorpo isolado, conjugado de anticorpo-fármaco, molécula de ácido nucleico, célula hospedeira, e, composição farmacêutica |
| BR112017000939A2 (pt) | 2014-07-21 | 2017-11-14 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico de cll-1 |
| AU2015292744C1 (en) * | 2014-07-21 | 2021-01-21 | Novartis Ag | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor |
| EP3172231B1 (en) | 2014-07-24 | 2021-05-05 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
| JP6588084B2 (ja) * | 2014-08-19 | 2019-10-09 | ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｓｅａ４抗原に特異的なキメラ抗原受容体 |
| TWI751102B (zh) | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | 對ｃｄ１９具專一性之抗體及嵌合抗原受體 |
| ES2738705T3 (es) * | 2014-09-19 | 2020-01-24 | Hope City | Linfocitos T de receptor de antígeno quimérico coestimulante que se dirigen a IL13R 2 |
| US12048718B2 (en) * | 2016-06-07 | 2024-07-30 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft | Chimeric antigen receptor and CAR-T cells that bind BCMA |
-
2017
- 2017-06-07 US US16/307,854 patent/US12048718B2/en active Active
- 2017-06-07 SG SG10202012157QA patent/SG10202012157QA/en unknown
- 2017-06-07 CN CN201780035831.4A patent/CN109641012A/zh active Pending
- 2017-06-07 CN CN202610595684.7A patent/CN122483218A/zh active Pending
- 2017-06-07 AU AU2017276706A patent/AU2017276706B2/en active Active
- 2017-06-07 CA CA3026778A patent/CA3026778A1/en active Pending
- 2017-06-07 SG SG11201810697QA patent/SG11201810697QA/en unknown
- 2017-06-07 WO PCT/EP2017/063862 patent/WO2017211900A1/en not_active Ceased
- 2017-06-07 ES ES17729846T patent/ES3068946T3/es active Active
- 2017-06-07 KR KR1020237003879A patent/KR20230042703A/ko not_active Ceased
- 2017-06-07 EP EP17729846.0A patent/EP3463396B1/en active Active
- 2017-06-07 JP JP2018564975A patent/JP2019527537A/ja active Pending
- 2017-06-07 EP EP26161870.6A patent/EP4737481A3/en active Pending
- 2017-06-07 KR KR1020187038249A patent/KR102497013B1/ko active Active
-
2022
- 2022-06-30 JP JP2022106290A patent/JP7646604B2/ja active Active
-
2024
- 2024-05-17 US US18/667,995 patent/US12351640B2/en active Active
- 2024-09-06 JP JP2024154170A patent/JP7805409B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7862028B2 (ja) | 免疫細胞活性化のための二重特異性抗体 | |
| AU2020204497B2 (en) | Bispecific binding proteins and uses thereof | |
| US20260078166A1 (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| US11795209B2 (en) | PVRIG polypeptides and methods of treatment | |
| KR102937285B1 (ko) | 신규 항-pd-l1 항체 | |
| JP6722189B2 (ja) | 単量体Ｆｃドメイン | |
| JP2025081649A (ja) | 多価多重特異性ｏｘ４０結合融合タンパク質 | |
| JP2017537925A5 (enExample) | ||
| KR20200110358A (ko) | 항-pd-1 항체 및 치료 방법 | |
| JP2022515223A (ja) | ヒトｐｄ－１に対する二機能性分子 | |
| JP2022506598A5 (enExample) | ||
| JP2017537919A5 (enExample) | ||
| JP2017522893A5 (enExample) | ||
| IL277398B1 (en) | Pd-l1 binding affimers, and uses related thereto | |
| CN107172880A (zh) | 含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途 | |
| AU2016370659A1 (en) | Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof | |
| JP2017537629A5 (enExample) | ||
| KR20180021786A (ko) | Lag-3-결합 분자 및 그 사용 방법 | |
| JP2020532969A5 (enExample) | ||
| CN110035773A (zh) | 新型抗ctla4抗体 | |
| JP2022542559A5 (enExample) | ||
| JP2022548112A5 (enExample) | ||
| JP2024539630A5 (enExample) | ||
| JP2021529539A5 (enExample) | ||
| AU2018346151B2 (en) | Transthyretin immunoglobulin fusions |